Global RNAi for Therapeutic Market Growth (Status and Outlook) 2025-2031

The global RNAi for Therapeutic market size is predicted to grow from US$ 351 million in 2025 to US$ 3221 million in 2031; it is expected to grow at a CAGR of 44.7% from 2025 to 2031.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

LPI (LP Information)' newest research report, the “RNAi for Therapeutic Industry Forecast” looks at past sales and reviews total world RNAi for Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected RNAi for Therapeutic sales for 2025 through 2031. With RNAi for Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi for Therapeutic industry.

This Insight Report provides a comprehensive analysis of the global RNAi for Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNAi for Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNAi for Therapeutic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi for Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi for Therapeutic.

This report presents a comprehensive overview, market shares, and growth opportunities of RNAi for Therapeutic market by product type, application, key players and key regions and countries.

Segmentation by Type:

siRNA

miRNA

shRNA

Segmentation by Application:

Cancer

Cardiovascular

HBV

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Please note: The report will take approximately 2 business days to prepare and deliver.